Abstract
High-risk non-muscle-invasive bladder cancer (NMIBC) has a heterogeneity and intensive surveillances after transurethral resection of bladder tumor (TURBT) are major factors of increased costs. Therefore, we aimed to develop optimized surveillance protocols based on the risk score-based substratifications to improve surveillance costs. We retrospectively evaluated 428 patients with primary high-risk NMIBC who underwent TURBT. Patients were substratified into intra-lower, intra-intermediate, and intra-higher groups or UUT-lower, UUT-intermediate, and UUT-higher groups by summing each of the independent risk factors of intravesical and UUT recurrences, respectively. The optimized surveillance protocols that enhance cost-effectiveness were then developed using real incidences of recurrence after TURBT. The 10-year total surveillance costs were compared between the European Association of Urology (EAU) guidelines-based and optimized surveillance protocols. The Kaplan–Meier curves of intravesical and UUT recurrence-free survivals were clearly separated among the substratified groups. The optimized surveillance protocols promoted a 43% reduction ($487,599) in the 10-year total surveillance cost compared to the EAU guidelines-based surveillance protocol. These results suggest that the optimized surveillance protocols based on risk score-based substratifications could potentially reduce over investigation and improve surveillance costs after TURBT in patients with primary high-risk NMIBC.
Similar content being viewed by others
Introduction
Bladder cancer (BC) is the ninth most common cancer worldwide1,2. BC is well known as one of the most expensive cancers to manage on a per capita basis3,4, and it is estimated to account for > 3% of all cancer-related medical costs5. Several studies have reported that most costs in patients with non-muscle-invasive BC (NMIBC) are related to surveillance after transurethral resection of bladder tumor (TURBT)6,7,8.
Several guidelines recommend risk-stratified surveillance protocols after TURBT in patients with NMIBC9,10,11. However, because those surveillance protocols were developed based on retrospective studies12,13,14,15, the optimal surveillance schedules remain indistinct. Because of the heterogeneity in high-risk NMIBC and the fact that risk factors differ between intravesical and upper urinary tract (UUT) recurrences12,15,16, we speculated that high-risk NMIBC could be substratified by each of the risk factors of intravesical and UUT recurrences and that the substratification-based surveillance protocols might improve surveillance costs in patients with high-risk NMIBC.
The aim of the present study was to substratify patients with high-risk NMIBC using risk scores calculated by summing each of the independent risk factors of intravesical and UUT recurrences and to develop optimized surveillance protocols based on these substratifications to improve surveillance costs after TURBT in patients with primary high-risk NMIBC.
Methods
Ethics statement
This study was performed in accordance with the ethical standards of the Declaration of Helsinki and approved by the Ethics Review Board of Mutsu General Hospital and Aomori Rosai Hospital (authorization numbers: H29-8 and 44, respectively). Pursuant to the provisions of the ethics committee and the ethics guidelines in Japan, a written informed consent was not required for the public disclosure of study information in the case of retrospective and/or observational study using materials, such as the existing documents.
Patient selection
A total of 480 patients with NMIBC who were treated from November 1993 to April 2019 at Mutsu General Hospital and Aomori Rosai Hospital were evaluated retrospectively. Of the 480 patients, 52 were excluded as they met one or more of the following exclusion criteria: (1) recurrent BC; (2) previous and/or simultaneous UUT urothelial carcinoma (UC); (3) pure carcinoma in situ (CIS) of the bladder; and (4) classified as low- or intermediate-risk based on the European Association of Urology (EAU) guidelines.
Evaluation of variables
The following variables were analyzed: age; sex; Eastern Cooperative Oncology Group performance status; body mass index; history of hypertension, diabetes mellitus, cardiovascular disease, and chronic kidney disease (CKD); number of tumors; tumor size; pathological T stage; tumor grade; variant histology of UC; lymphovascular invasion (LVI); postoperative intravesical instillation of chemotherapy and bacillus Calmette-Guérin (BCG); and second TURBT. Renal function was evaluated by estimated glomerular filtration rate (eGFR) using a modified version of the abbreviated Modification of Diet in Renal Disease Study formula for Japanese patients17 and CKD was defined as eGFR < 60 mL/min/1.73 m2. Tumor stage was assigned according to the 2009 TNM classification of the Union of International Cancer Control. Tumor grade was classified according to the 1973 World Health Organization classification system. Tumor grade at first TURBT was used in the analyses.
Follow-up protocol
Our follow-up protocol was based on the EAU guidelines (urine cytology and cystoscopy every 3Â months for 2Â years, every 6Â months for an additional 3Â years, and annually thereafter as well as abdominal and pelvic computed tomography [CT] and blood chemistry to evaluate renal function for contrast-enhanced CT annually; Table 1). Disease recurrence site was classified as intravesical and UUT. The first recurrence in each site after TURBT was recorded.
Substratification
We developed risk score-based substratifications using multivariable Cox proportional hazard regression analyses for intravesical and UUT recurrence-free survival (RFS). The risk scores were calculated by summing each of the independent risk factors of intravesical and UUT recurrences, and patients with high-risk NMIBC were substratified into intra-lower (0 score), intra-intermediate (1 score), and intra-higher (2 or 3 scores) groups or into UUT-lower (0 score), UUT-intermediate (1 score), and UUT-higher (2 scores) groups.
Optimized surveillance protocols
Using the risk score-based substratifications, optimized surveillance protocols that enhance cost-effectiveness were developed using real incidences of recurrence after TURBT. An intravesical recurrence detection rate ([number of patients with recurrence/number of patients with surveillance] × 100) of ≥ 1% during a certain period indicated that routine surveillance using urine cytology and cystoscopy was necessary in this period. On the other hand, an intravesical recurrence detection rate of < 1% during a certain period indicated that routine surveillance was not necessary in this period. Similarly, an UUT recurrence detection rate of ≥ 1% during a certain period indicated that routine surveillance via CT and blood chemistry was necessary in this period.
Outcome evaluations
Time to first intravesical and UUT recurrences, estimated surveillance cost per one recurrence detection, and 10-year total surveillance cost using the EAU guidelines-based and optimized surveillance protocols were recorded. To estimate the cost–benefit, surveillance costs for detecting one recurrence were calculated (total surveillance cost in a follow-up period/number of patients with recurrence) using an exchange rate of 100 yen to one US dollar. Medical costs were $45 for urine cytology, $95 for cystoscopy, $267 for CT with contrast media, and $24 for blood chemistry. The cost of prescriptions, medications, and doctor fees were not included herein. The 10-year total surveillance cost was compared between the EAU guidelines-based and optimized surveillance protocols.
Statistical analysis
Statistical analyses were performed using SPSS version 24.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5.03 (GraphPad Software, San Diego, CA, USA). Quantitative variables were expressed as median with interquartile range. RFS was evaluated using the Kaplan–Meier method and compared using the log-rank test. A P value of < 0.05 indicated statistical significance.
Results
Patients’ backgrounds
The median age of the patients and median follow-up period after TURBT were 72Â years and 54Â months, respectively (Table 2). Although 90 (21%) patients were treated with postoperative intravesical instillation of BCG, no patient was treated with maintenance BCG therapy. Figure S1 shows our schedule of induction course of BCG therapy.
Substratification
At the end of the follow-up periods, intravesical and UUT recurrences occurred in 140 and 22 patients, respectively. In multivariable analysis, CKD, grade 3, and tumor size ≥ 30 mm were selected as independent risk factors of shorter intravesical RFS. Similarly, in multivariable analysis, CKD and grade 3 were selected as independent risk factors of shorter UUT RFS (Table 3). Risk scores were calculated by summing each of the independent risk factors of shorter intravesical and UUT RFS (Table 3), and patients with high-risk NMIBC were substratified into intra-lower (0 score, n = 181), intra-intermediate (1 score, n = 158), and intra-higher (2 or 3 scores, n = 89) groups or into UUT-lower (0 score, n = 210), UUT-intermediate (1 score, n = 171), and UUT-higher (2 scores, n = 47) groups (Fig. 1A). The Kaplan–Meier curves of intravesical RFS could be clearly separated among the three groups (Fig. 1B; intra-lower vs. intra-intermediate, P = 0.004; intra-intermediate vs. intra-higher, P = 0.002). Similarly, the Kaplan–Meier curves of UUT RFS could be clearly separated among the three groups (Fig. 1C; UUT-lower vs. UUT-intermediate, P = 0.034; UUT-intermediate vs. UUT-higher, P = 0.024).
Time course of recurrence
The first intravesical recurrence occurred most frequently 3 months after TURBT in all patients with high-risk NMIBC (Fig. 2A; n = 31, 22%) and gradually decreased thereafter. Intra-lower and intra-intermediate patients had similar time courses of recurrence (Fig. 2B). Intra-higher patients had significantly more early recurrences within 1 year after TURBT than intra-lower (67% vs. 44%, P < 0.001) and intra-intermediate patients (67% vs. 45%, P = 0.027). Only 4 (8.9%) recurrences occurred after 30 months in intra-higher patients (Fig. 2B).
The first UUT recurrence occurred throughout the entire follow-up period except after 84 months in all patients with high-risk NMIBC (Fig. 2C). UUT-intermediate patients had a time course similar to that of all patients with high-risk NMIBC (Fig. 2D). No UUT recurrence occurred after 48 months in UUT-higher patients (Fig. 2D).
Optimized surveillance protocols
Almost all intra-intermediate patients with intravesical recurrence had intravesical recurrence detection rates of ≥ 1% throughout the entire follow-up period, except at 84 months after TURBT (Fig. 2E). On the other hand, intra-higher patients had intravesical recurrence detection rates of < 1% after 30 months, except at 54, 72, and 120 months (Fig. 2E).
UUT-lower, UUT-intermediate, and UUT-higher patients had UUT recurrence detection rates of < 1% throughout the entire follow-up period, except at 60 months (UUT-lower); 36, 42, 48, 60, and 84 months (UUT-intermediate); and 6, 9, 18, and 48 months (UUT-higher) (Fig. 2F).
Based on previously discussed criteria (i.e., a recurrence detection rate of < 1% during a certain period indicated that routine surveillance was not necessary in this period), optimized surveillance protocols were developed to improve surveillance costs (Table 1).
Economic outcomes
All patients with high-risk NMIBC had a higher (> $5000) estimated cost of cystoscopy and urine cytology per one recurrence detection at 9, 18, 21, 24, 42, 48, 54, 60, 84, 96, and 108 months (Fig. 3A). On the other hand, intra-higher patients had a lower (< $5000) estimated cost of cystoscopy and urine cytology per one recurrence detection throughout the entire follow-up period (Fig. 3B).
All patients with high-risk NMIBC had an extremely high (> $30,000) estimated cost of CT and blood chemistry per one recurrence detection at 12, 24, 48, 72, and 84 months (Fig. 3C). On the other hand, UUT-lower, UUT-intermediate, and UUT-higher patients had lower (< $30,000) estimated costs of CT and blood chemistry per one recurrence detection throughout the entire follow-up period (Fig. 3D).
The optimized surveillance protocols promoted a 43% lower ($487,599) 10-year total surveillance cost compared with the EAU guidelines-based surveillance protocol (Fig. 3E).
Only three intra-lower patients potentially failed intravesical recurrence detection using the optimized surveillance protocol (Fig. 4A). Similarly, two UUT-lower and four UUT-intermediate patients potentially failed UUT recurrence detection using the optimized surveillance protocol (Fig. 4B).
Discussion
To the best of our knowledge, this is the first study to evaluate the cost-effectiveness of optimized surveillance protocols using risk score-based substratifications in patients with primary high-risk NMIBC. The present study showed that patients with high-risk NMIBC could be substratified by each of the risk factors of intravesical and UUT recurrences, and the optimized surveillance protocols based on the substratifications promoted a 43% reduction in the 10-year total surveillance cost as compared with the EAU guidelines-based surveillance protocol. The key points of cost reduction were the substratification of high-risk NMIBC and the decrease in the frequency of unnecessary cystoscopy, urine cytology, and CT. Although a validation study is needed, optimized surveillance protocols created from risk score-based substratifications might improve surveillance costs after TURBT in patients with primary high-risk NMIBC.
Several guidelines recommend intensive surveillance using cystoscopy and urine cytology after TURBT in patients with high-risk NMIBC9,10,11. Although intensive surveillance may detect recurrences before progression to muscle invasive BC18, it results in increased surveillance costs. Strope et al. reported that costs to manage patients with NMIBC have increased since 1993, and this increase was driven by surveillance after TURBT6. Likewise, several studies reported that most costs are driven by surveillance using cystoscopy7,8. Because the evidence on this topic is lacking, an optimal surveillance protocol that balances oncological benefits with cost-effectiveness remains indistinct. One possible strategy to improve surveillance costs is the substratification of high-risk NMIBC. Because of the heterogeneity of high-risk NMIBC16,19, we speculated that it could be substratified by risk factors of intravesical recurrence. Results showed that the Kaplan–Meier curves of intravesical RFS could be clearly separated among intra-lower, intra-intermediate, and intra-higher patients in the present study (Fig. 1B). Moreover, the time course of intravesical recurrence suggests that less frequent surveillance after 30 months might be sufficient to improve surveillance costs for intra-higher patients, considering that almost all recurrences in intra-higher patients occurred within 30 months after TURBT (Fig. 2B, 91%). Liquid biopsy is an alternative potential method for the substratification of high-risk NMIBC and surveillance after TURBT20,21,22. Although liquid biopsy improves the sensitivity and specificity in the detection of recurrence, it may not be used for improving surveillance costs because of its high cost21,23. Although it is not easy to develop a “one-size-fits-all” surveillance protocol because of the heterogeneity of high-risk NMIBC and the differences in medical systems among nations, these results may provide the idea that optimized surveillance protocols constructed from risk score-based substratifications can be used to improve surveillance costs in patients with high-risk NMIBC.
Although several guidelines recommend regular UUT imaging after TURBT in patients with high-risk NMIBC9,10,11, no prospective validation study has supported these recommendations. Regular UUT imaging can detect asymptomatic UUT recurrence. However, no study has demonstrated an association between the detection of asymptomatic UUT recurrence and survival benefits. In the present study, cancer-specific survival (CSS) and overall survival (OS) after UUT recurrence were not significantly different between patients with asymptomatic and symptomatic UUT recurrences (Fig. S2A; CSS, P = 0.911, Fig. S2B; OS, P = 0.555). In addition, most UUT recurrence detection rates were < 1% throughout the entire follow-up period (Fig. 2F). Similarly, Sternberg et al. reported that of 3074 CT examinations, only 15 (0.5%) were able to detect an asymptomatic UUT recurrence24. These results suggest that the frequency and duration of regular UUT imaging might need to be reconsidered to balance oncological benefits with cost-effectiveness. Further study is needed to determine the optimal UUT imaging schedules in patients with high-risk NMIBC.
Not only the clinical and pathological factors of tumors but also other clinical factors of patients have a significant impact on intravesical and UUT recurrence after TURBT25,26. In the present study, CKD was selected as an independent risk factor of both of intravesical and UUT recurrences and added into risk scores. Several studies support this relationship between CKD and poor oncological outcomes in patients with NMIBC27,28,29. These results suggest that preoperative CKD cannot be ignored in the substratification of patients with high-risk NMIBC. Several possible mechanisms were presumed. One is chronic inflammation and oxidative stress, which are increased in patients with CKD30. Oxidative stress activates chronic inflammation and promotes proliferation, carcinogenesis, invasion of tumor cells, angiogenesis, and chemoresistance31. Another mechanism is the reduction in DNA repair ability. Reduction in DNA repair ability and chromosomal abnormalities were observed in cells of patients with CKD32. The third mechanism is immune dysfunction. The uremic environment induces immune system dysfunction, including macrophage hypoactivity, altered antigen-presenting cell function, increased helper T-cell 1/2 ratio, impaired T-cell activation, and decreased B-cell count33. Although no study has investigated the direct association between these mechanisms and NMIBC with CKD, CKD might be useful for substratifying patients with high-risk NMIBC. Further clinical and basic research is needed.
The present study has several limitations. First, this study employed a retrospective design, which prevented us from making definitive conclusions. Second, a relatively small number of patients were enrolled. Third, only 21% of the patients received intravesical instillation of BCG, none of whom received maintenance BCG therapy. In the study using the National Cancer Database that captured data on more than 70% of newly diagnosed cancer cases in the United States, Balakrishnan et al. have reported that of 47,694 patients with high-risk NMIBC, only 24% received BCG therapy regardless guideline recommendations34. Thus, the low BCG therapy rate in the present study may reflect a real-world clinical practice. Fourth, only a limited number of patients underwent second TURBT because it is difficult to perform second TURBT in all patients with high-risk NMIBC in clinical practice considering patients’ comorbidities and an operating room capacity. The small number of patients who received intravesical instillation of BCG and underwent second TURBT might cause the early recurrence. Finally, the prolonged study period may have increased the inaccuracy of pathology interpretations.
In conclusion, the optimized surveillance protocols established from risk score-based substratifications could potentially reduce overinvestigation and improve surveillance costs after TURBT in patients with primary high-risk NMIBC.
Data availability
The minimal data set generated during the present study are available from the corresponding author upon reasonable request.
References
Yoshida, T., Kates, M., Fujita, K., Bivalacqua, T. J. & McConkey, D. J. Predictive biomarkers for drug response in bladder cancer. Int. J. Urol. 26, 1044–1053 (2019).
Choo, S. H. et al. Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A web-based survey. Int. J. Urol. 26, 1121–1127 (2019).
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21, 1315–1330 (2003).
Mossanen, M. et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: An analysis based on risk categories. World J. Urol. 37, 2059–2065 (2019).
Svatek, R. S. et al. The economics of bladder cancer: Costs and considerations of caring for this disease. Eur. Urol. 66, 253–262 (2014).
Strope, S. A., Ye, Z., Hollingsworth, J. M. & Hollenbeck, B. K. Patterns of care for early stage bladder cancer. Cancer 116, 2604–2611 (2010).
Yeung, C., Dinh, T. & Lee, J. The health economics of bladder cancer: An updated review of the published literature. Pharmacoeconomics 32, 1093–1104 (2014).
Skolarus, T. A., Ye, Z., Zhang, S. & Hollenbeck, B. K. Regional differences in early stage bladder cancer care and outcomes. Urology 76, 391–396 (2010).
Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol. 196, 1021–1029 (2016).
Babjuk, M. et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur. Urol. 76, 639–657 (2019).
Taylor, J., Becher, E. & Steinberg, G. D. Update on the guideline of guidelines: Non-muscle-invasive bladder cancer. BJU Int. https://doi.org/10.1111/bju.14915 (2019).
Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–465 (2006) (discussion 475–467).
Soukup, V. et al. Follow-up after surgical treatment of bladder cancer: A critical analysis of the literature. Eur. Urol. 62, 290–302 (2012).
Holmang, S. & Strock, V. Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years?. Eur. Urol. 61, 503–507 (2012).
Millan-Rodriguez, F., Chechile-Toniolo, G., Salvador-Bayarri, J., Huguet-Perez, J. & Vicente-Rodriguez, J. Upper urinary tract tumors after primary superficial bladder tumors: Prognostic factors and risk groups. J. Urol. 164, 1183–1187 (2000).
Oughton, J. B. et al. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): A protocol for a randomised controlled feasibility study. BMJ Open 7, e017913 (2017).
Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982–992 (2009).
Holmang, S., Hedelin, H., Anderstrom, C. & Johansson, S. L. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol. 153, 1823–1826 (1995) (discussion 1826–1827).
Fujita, N. et al. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. Urol. Oncol. 38(795), e799-795.e717 (2020).
Mitra, A. P. Molecular substratification of bladder cancer: Moving towards individualized patient management. Ther. Adv. Urol. 8, 215–233 (2016).
Crocetto, F. et al. Liquid biopsy in bladder cancer: State of the art and future perspectives. Crit. Rev. Oncol. Hematol. 170, 103577 (2022).
Lodewijk, I. et al. Liquid biopsy biomarkers in bladder cancer: A current need for patient diagnosis and monitoring. Int. J. Mol. Sci. 19, 2514 (2018).
Chen, C. K., Liao, J., Li, M. S. & Khoo, B. L. Urine biopsy technologies: Cancer and beyond. Theranostics. 10, 7872–7888 (2020).
Sternberg, I. A. et al. Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. J. Urol. 190, 1187–1191 (2013).
Hwang, E. C. et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: A retrospective cohort study. Int. J. Urol. 18, 769–776 (2011).
Li, C. E. et al. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. Int. Urol. Nephrol. 48, 993–999 (2016).
Blute, M. L. Jr. et al. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m(2)) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 120, 387–393 (2017).
Rausch, S. et al. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression–introducing a novel prognostic model for bladder cancer recurrence. Urol. Oncol. 32, 1178–1183 (2014).
Fujita, N. et al. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy. Urol. Oncol. 39(191), e199-191.e116 (2021).
Oberg, B. P. et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 65, 1009–1016 (2004).
Reuter, S., Gupta, S. C., Chaturvedi, M. M. & Aggarwal, B. B. Oxidative stress, inflammation, and cancer: How are they linked?. Free Radic. Biol. Med. 49, 1603–1616 (2010).
Schupp, N., Stopper, H. & Heidland, A. DNA damage in chronic kidney disease: Evaluation of clinical biomarkers. Oxid. Med. Cell Longev. 2016, 3592042 (2016).
Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3, 1526–1533 (2008).
Balakrishnan, A. S., Washington, S. L. 3rd., Meng, M. V. & Porten, S. P. Determinants of guideline-based treatment in patients with cT1 bladder cancer. Clin. Genitourin. Cancer. 17, e461–e471 (2019).
Acknowledgements
The authors thank Enago (http://www.enago.jp) for their English language review. This work was supported by a Grant-in-Aid for Scientific Research (Nos. 17K11119, 18K09157, and 19H05556) from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Contributions
All authors reviewed the manuscript. N.F.: conception and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and statistical analysis. S.H.: conception and design, critical revision of the manuscript, and obtaining funding. M.M., Y.T., H.Y., H.I., T.Y., Y.H., and K.Y.: acquisition of data. T.Y.; obtaining funding. C.O.: obtaining funding and supervision.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Fujita, N., Hatakeyama, S., Momota, M. et al. Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer. Sci Rep 12, 13786 (2022). https://doi.org/10.1038/s41598-022-17973-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-022-17973-8
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.